[The proliferation, phenotype change and anti-tumor activity of cytokine induced killer cells].
OBJECTIVE
To study the growth regularity, the phenotype change and the cytotoxicity of CIK cells.


METHODS
The number of CIK cells was counted by living cell counting in different culturing time to observe the growth of the CIK cells, and the phenotype change of the CIK cells was detected by flow cytometry. Meanwhile cytotoxicity of CIK cells to tumor cell lines was also detected by CytoTox96 non-radiated cytotoxicity kit.


RESULTS
After stimulated by cytokines and anti-CD3 antibody, CIK cells can proliferate significantly. The cell number of CIK was increased to 473.28+/-27.53 fold in serum-free medium plus auto-serum, 218.24+/-16.86 fold in serum-free medium and only 11.52+/-1.04 fold in RPMI1640 plus fetal FCS, respectively. The CD3(+)+CD8(+), CD3(+)+CD56(+), CD226(+)+CD11a(+) and CD305(+)+CD11a(+) cells were increased with the progression of the cultural time and the CD3(+)+CD4(+) cells were decreased with the progression of cultural time. The cytotoxicity of CIK cells to tumor cell lines was significantly higher than that of LAK cells (P<0.01) and its cytotoxicity was increased with progression of the cultural time.


CONCLUSIONS
CIK cells have strong proliferative ability and higher cytotoxicity to tumor cells in vitro, which could be used as a potential anti-tumor adoptive immunotherapy in clinic.
Cao
Jian-ping
JP
Department of Experimental Medicine, General Hospital of Shenyang Military Command, Shenyang 110016, China. jianpingpp@hotmail.com
Jiang
Zhi-ming
ZM
Zhang
Xiao-chen
XC
Lin
Di
D
Chen
Wei
W
Sun
Ying-hui
YH
Ma
Dong-chu
DC
D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D040881:CD11a Antigen / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology; D019002:CD56 Antigen / Q000276:immunology; D016827:CD8 Antigens / Q000276:immunology; D002460:Cell Line; D049109:Cell Proliferation; D002478:Cells, Cultured; D055612:Cytokine-Induced Killer Cells / Q000166:cytology* / Q000276:immunology / Q000502:physiology*; D005434:Flow Cytometry; D018922:HL-60 Cells; D006801:Humans; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D000098862:T Lineage-Specific Activation Antigen 1
D000945:Antigens, Differentiation, T-Lymphocyte; D040881:CD11a Antigen; D000098862:T Lineage-Specific Activation Antigen 1; D017252:CD3 Complex; D019002:CD56 Antigen; D016827:CD8 Antigens